Clinical trial
A phase Ib, open-label, multicenter study to investigate the pharmacokinetics, pharmacodynamics, and safety of tocilizumab following subcutaneous administration to patients with polyarticular-course juvenile idiopathic arthritis
The primary objective is to characterize the pharmacokinetics of subcutaneous tocilizumab (SC TCZ) in patients with pcJIA.
| Category | Value |
|---|---|
| Study start date | 2013-06-20 |